32.45
+2.04%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medigen Biotechnology
Its shares trade on Taipei Exchange under the ticker 3176.TWO. It has been listed since 23 November 2011. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.58bn and a net loss of TWD 108.8m. At that date it held total assets of TWD 6.18bn and shareholders' equity of TWD 1.55bn.
Medigen Biotechnology Corp. engages in biopharmaceutical research and development. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-11-23. The firm is engaged in the licensing of technologies, the provision of technical services and testing services of nucleic acids. The firm's products and services include human leukocyte antigen (HLA) ABDR typing reagents, HLA typing and testing services, HLA SBT high-resolution typing reagents, HLA ABCDRDQ typing kits, nucleic acid testing reagents for the genotyping of human platelet, nucleic acid extraction instruments and reagents and blood screening specialized automated nucleic acid detection platforms. The company also provides medical beauty care products. The firm distributes its products in Taiwan market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Nov 2011
- Employees
- 32
- Website
- medigen.com.tw/en/home ↗
Leadership
Pay as last reported
- Mr. Shi-Chung ChangChairman of the Board, General Manager, since 2000TWD 7.8m
- Ms. Feng-Hua ChenSenior Finance Manager-Administrative and Accounting Department, Corporate Governance Officer
- Mr. Chieh-Liang LinChief Scientific Officer-Cell Therapy DepartmentTWD 2.7m
- Ms. Ya-Ling ChiangDeputy General Manager-Operations and Management DepartmentTWD 3.3m
- Ms. Chin-Yen ChenDeputy General Manager-Drug Development DepartmentTWD 2.6m
- Ms. I-Ju ChenManager of Accounting-Administrative and Accounting Department
- Ms. Tse-Ling ChangDirectorTWD 114,000
- Ms. Ming-Li ChuangDirectorTWD 108,000
- Mr. Tzu-Liang HuangDirectorTWD 114,000
- Mr. Pei-Wei ChenIndependent DirectorTWD 304,000
- Mr. Shui-Ming ChuangIndependent DirectorTWD 304,000
- Ms. Sheue-Rong LinIndependent DirectorTWD 106,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has a specialized focus on biopharmaceutical research and development.
- It offers diverse services including HLA typing and nucleic acid testing.
- Products are distributed in both Taiwan and overseas markets.
Weaknesses
- The firm operates with a very small workforce of only 32 employees.
- It relies on licensing technologies rather than solely internal innovation.
- The business includes medical beauty care which may dilute core focus.
Opportunities
- Expanding technical services for nucleic acid testing can drive growth.
- Leveraging automated nucleic acid detection platforms enhances service capacity.
- Distributing products to additional overseas markets increases revenue potential.
Threats
- Competition in the biotechnology sector poses significant market risks.
- Regulatory changes in healthcare can impact testing service operations.
- Small employee count limits scalability and operational resilience.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.